Palvella Therapeutics’ (PVLA) Buy Rating Reaffirmed at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $38.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 35.76% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, March 26th. They set a “buy” rating and a $45.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock. Scotiabank started coverage on Palvella Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. Finally, TD Cowen assumed coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and an average target price of $43.50.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $27.99 on Tuesday. The company has a market capitalization of $314.08 million, a price-to-earnings ratio of -2.31 and a beta of 0.54. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The company has a fifty day moving average price of $20.54.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PVLA. Suvretta Capital Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter worth about $8,574,000. BVF Inc. IL bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth $8,359,000. Samsara BioCapital LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth about $8,154,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $7,847,000. Finally, Adams Street Partners LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $4,916,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.